報價延遲最少15分鐘:2026/07/31 00:52 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.3 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.32/-8.04
|
|
企業價值
42.06M
|
| 資產負債 |
|
每股賬面淨值
-2.21
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases. |
